BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 124 filers reported holding BLUEBIRD BIO INC in Q3 2014. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,100,792 | -33.8% | 159,074 | -39.5% | 0.18% | -29.4% |
| Q3 2022 | $1,663,000 | -22.7% | 262,767 | -49.4% | 0.25% | +32.6% |
| Q2 2022 | $2,151,000 | -14.6% | 519,477 | -0.0% | 0.19% | -12.4% |
| Q1 2022 | $2,520,000 | -16.7% | 519,485 | +71.5% | 0.22% | -5.7% |
| Q4 2021 | $3,025,000 | -7.8% | 302,852 | +76.4% | 0.23% | -2.5% |
| Q3 2021 | $3,281,000 | +17.1% | 171,700 | +96.0% | 0.24% | +27.6% |
| Q2 2021 | $2,801,000 | +55.9% | 87,600 | +47.0% | 0.18% | +43.4% |
| Q1 2021 | $1,797,000 | -51.4% | 59,596 | -30.3% | 0.13% | -48.4% |
| Q4 2020 | $3,700,000 | -3.8% | 85,519 | +19.9% | 0.25% | -1.6% |
| Q3 2020 | $3,848,000 | -24.0% | 71,319 | -14.0% | 0.25% | -26.2% |
| Q2 2020 | $5,060,000 | +6.0% | 82,900 | -20.2% | 0.34% | -9.0% |
| Q1 2020 | $4,775,000 | -47.6% | 103,900 | 0.0% | 0.38% | -32.7% |
| Q4 2019 | $9,117,000 | +2167.9% | 103,900 | +896.3% | 0.56% | +5009.1% |
| Q2 2014 | $402,000 | – | 10,429 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
| qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
| Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
| Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
| Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
| HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
| Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
| PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
| Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
| Summit X, LLC | 103,424 | $651,000 | 0.19% |